Revance Therapeutics Expands Commercialization Team to Gear Up for Product Launch of RT002 Injectable
April 02 2018 - 4:05PM
Business Wire
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology
company developing neuromodulators for use in treating aesthetic
and underserved therapeutic conditions, today announced the
appointments of Dustin Sjuts as Vice President of Strategy and
Sales, Aesthetic and Therapeutic; Ben Putman as Vice President of
Digital; and Marc Korenberg as Senior Director of Commercial
Operations. In addition, Erica Bazerkanian has been promoted to
Vice President of Marketing, Aesthetics and Therapeutics. All four
positions are newly established and will report to Todd Zavodnick,
Chief Commercial Officer and President, Aesthetics &
Therapeutics, who leads the company’s commercial operations and
launch preparations for DaxibotulinumtoxinA for Injection (RT002)
in the treatment of glabellar (frown) lines.
In his new role at Revance, Mr. Sjuts will head all product
sales activities, championing strategies to enhance physician
relations and drive new product adoption. Most recently, he held
leadership positions at Nestle Skin Health, including Business Unit
Head in China and Senior Director of Marketing in the U.S. In
China, he was responsible for the medical aesthetics commercial
organization, leading the development and execution of the medical
solutions strategy. Prior to this, Mr. Sjuts was Senior Vice
President of Franchise Operations for Alphaeon. Previously, he
served as Director of Sales in Eye Care and as Senior Regional
Manager of Aesthetics at Allergan.
Mr. Putman will lead digital marketing and strategy activities
in his new role at Revance, focused on delivering optimal customer
outreach and experiences. Prior to joining the Company, he served
as Senior Vice President, General Manager and Senior Vice President
of Creative Technology and Innovation at JUICE Pharma Advertising.
Throughout his advertising career, he has led digital marketing
strategy efforts for multiple pharmaceutical and healthcare clients
and has worked on over a dozen new product launches. Previously,
Mr. Putman was Director of Technology at FCB Health and Director of
Web Development at Harrison & Star.
In his new role, Mr. Korenberg will manage commercial operations
activities at Revance, including customer excellence and
relationship management, commercial analytics, commercial programs,
and commercial financial management. Most recently, he was Director
of Commercial, International at Allergan, after the acquisition of
Zeltiq Aesthetics, Inc., where Marc served as the Director of
International Finance and Operations. Prior to this, he was General
Manager at Powersports East. Mr. Korenberg began his career in
corporate finance and investment banking at UBS Investment
Bank.
Ms. Bazerkanian’s new role includes responsibility for strategic
marketing, launch planning, product development and public
relations. Prior to her promotion, she served as Head, Strategic
Marketing at Revance, overseeing both aesthetic and therapeutic
marketing and public relations initiatives. Previously, she was
Senior Director of Marketing at Kythera Biopharmaceuticals, heading
early market strategy and product planning for a first-of-its-kind
aesthetic injectable. Prior to this, she worked on multiple product
launches at Amgen in roles with increasing responsibility across
sales, business analysis and marketing promotions.
“Revance continues to attract accomplished talent in the
industry, and we are pleased to announce the addition of these
seasoned leaders to our commercial team,” said Zavodnick. “Each of
these individuals possesses a proven track record and will play an
important role as we implement the Revance Product Launch Velocity
Plan for the successful commercialization of Revance’s lead product
candidate RT002 and expand our presence in both aesthetics and
therapeutic medicine.”
About Revance Therapeutics, Inc.
Revance Therapeutics is a biotechnology company developing
neuromodulators for use in treating aesthetic and underserved
therapeutic conditions, including muscle movement disorders and
pain. The company's lead drug candidate, DaxibotulinumtoxinA for
Injection (RT002), is currently in development for the treatment of
glabellar lines, cervical dystonia and plantar fasciitis, with the
potential to be the first long-acting neuromodulator. Revance has
developed a proprietary, stabilizing excipient peptide technology
designed to create novel, differentiated therapies. The company has
a comprehensive pipeline based upon its peptide technology,
including injectable and topical formulations of
daxibotulinumtoxinA. More information on Revance may be found at
www.revance.com.
"Revance Therapeutics" and the Revance logo are registered
trademarks of Revance Therapeutics, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180402005685/en/
INVESTORSRevance Therapeutics, Inc.:Jeanie Herbert, (714)
325-3584jherbert@revance.comorBurns McClellan, Inc.:Ami Bavishi,
(212) 213-0006abavishi@burnsmc.comorMEDIAGeneral
Media:TOGORUN:Mariann Caprino, (917)
242-1087m.caprino@togorun.comorTrade Media:Nadine Tosk, (504)
453-8344nadinepr@gmail.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Apr 2023 to Apr 2024